Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5331 - Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: results from the PROSPER study

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Cytotoxic Therapy

Tumour Site

Prostate Cancer

Presenters

Bertrand Tombal

Citation

Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284

Authors

B. Tombal1, M. Hussain2, D. Penson3, G. Attard4, C.N. Sternberg5, D. Phung6, R. Morlock7, K. Modelska8, K. Ramaswamy9, C. Ivanescu10, F. Saad11

Author affiliations

  • 1 Department Of Urology, Cliniques Universitaires Saint-Luc, 1200 - Brussels/BE
  • 2 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 60611 - Chicago/US
  • 3 Department Of Urologic Surgery, Vanderbilt University Medical Center, 37232 - Nashville/US
  • 4 Medical Oncology, The Institute of Cancer Research and The Royal Marsden, SM2 5NG - Surrey/GB
  • 5 Medical Oncology, San Camillo Forlanini Hospital, 00152 - Rome/IT
  • 6 Data Science, Astellas Pharma Inc, 23182 - Leiden/NL
  • 7 Health Economics And Outcomes Research, Astellas Pharma Inc, Northbrook/US
  • 8 Medical Oncology, Pfizer Inc., 94105 - San Francisco/US
  • 9 Oncology, Pfizer Inc., New York/US
  • 10 Advisory Analytics, IQVIA, Hoofddorp/NL
  • 11 Urology, Centre Hospitalier de l’Université de Montréal/CRCHUM, H2X 3J4 - Montreal/CA
More

Resources

Abstract 5331

Background

The PROSPER trial (NCT02003924) showed a clinically and statistically significant improvement in metastasis-free survival (HR 0.292 [95% CI 0.241, 0.352], p < 0.0001) with enzalutamide (ENZ; n = 933) versus placebo (PBO; n = 468) in asymptomatic men with nmCRPC and prostate-specific antigen doubling time ≤10 months. All men without prior orchiectomy continued androgen deprivation therapy. We assessed the impact of ENZ on prostate cancer symptoms (PCS) and health-related quality of life (HRQoL).

Methods

PCS and HRQoL were assessed at baseline (BL) and subsequently every 16 weeks, using the EORTC Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) and the EuroQol 5-domain 5-level (EQ-5D-5L). Clinically meaningful symptom worsening in PCS scores was defined using thresholds derived as 1/2 standard deviation at BL. Clinically meaningful deterioration in EQ-5D-5L visual analogue scale was defined using the pre-established threshold of 7. Time to first confirmed (at two consecutive visits) and unconfirmed (one visit) deterioration in QLQ-PR25 and EQ-5D-5L scores were assessed using Kaplan-Meier estimates and Cox models.

Results

Completion rates were high for patients (pts) remaining on study (>85% for all visits). BL scores were similar between arms and showed low symptom burden (including urinary and bowel symptoms) and high HRQoL. The proportion of pts reporting either no change or improvement in HRQoL and PCS scores at week 49 was higher with ENZ (67 − 87%) than PBO (62 − 81%). Over the course of treatment, ENZ significantly delayed worsening of symptoms including urinary and bowel symptoms/function (Table). In contrast, ENZ significantly increased the risk of worsening of hormonal treatment related symptoms compared to PBO (Table).Table: 807P

Baseline scoresTime to deterioration or symptom worsening
Instrument/scaleENZ (n = 933)PBO (n = 468)ConfirmedUnconfirmed
nMean (SD)nMean (SD)Hazard ratio (95% CI)Hazard ratio (95% CI)
QLQ-PR25
PRAID*14420.37 (27.91)6724.38 (33.63)NENE
PRBOW*8845.14 (8.39)4394.65 (7.70)0.72 (0.59, 0.89)0.80 (0.67, 0.95)
PRHTR*88414.92 (12.50)43915.79 (13.30)1.29 (1.02, 1.63)1.30 (1.08, 1.59)
PRSAC88411.86 (20.05)43911.77 (20.63)0.98 (0.77, 1.24)1.04 (0.83, 1.31)
PRSFU4953.40 (23.44)2448.26 (26.35)NENE
PRURI*88420.69 (17.55)43920.02 (17.68)0.58 (0.46, 0.72)0.72 (0.60, 0.87)
EQ-5D-5L
EQ-VAS88476.17 (16.92)43977.53 (15.97)0.75 (0.63, 0.90)0.83 (0.71, 0.97)
*

Higher scores represent higher level of symptoms/more pain; Higher scores represent higher level of functioning/better quality of life;

Statistically significant at 0.05. Results for the EORTC-QLQ-PR25 PRSFU and PRAID were not estimated because of the low sample size and small number of events. CI=confidence interval; ENZ=enzalutamide; EQ-5D-5L=EuroQol 5-domain 5-level questionnaire; EQ-VAS=EuroQol visual analogue scale; NE=not estimated; PBO=placebo; PRAID=incontinence aids; PRBOW=bowel symptoms/function; PRHTR=hormonal treatment-related symptoms; PRSAC=sexual activity; PRSFU=sexual functioning; PRURI=urinary symptoms and problems; QLQ-PR25=EORTC Quality of Life Questionnaire-Prostate 25; SD=standard deviation.

Conclusions

In addition to delayed disease progression in the PROSPER trial, ENZ prolonged urinary and bowel symptom control and delayed decline in HRQoL scores versus PBO.

Clinical trial identification

NCT02003924.

Legal entity responsible for the study

Astellas Pharma Inc and Pfizer Inc.

Funding

This study was funded by Astellas Pharma Inc and Pfizer Inc, the co-developers of enzalutamide.

Editorial Acknowledgement

Editorial assistance was provided by Lauren Smith from Complete HealthVizion, funded by Astellas Pharma Inc and Pfizer Inc, the co-developers of enzalutamide.

Disclosure

B. Tombal: Personal fees: Astellas, during the conduct of the study; Grants: Bayer, Janssen, Sanofi, Ferring; Personal fees: Bayer, Janssen, Sanofi, Ferring, Amgen; Non-financial support: Ferring, outside the submitted work. M. Hussain: Other: Genentech/Roche, Abbvie, Bayer, Onclive, Pfizer, PCCTC, AstraZeneca, outside the submitted work; Patent pending: Systems and methods for tissue imaging, Method of treating cancer, Dual inhibition of MET and VEGF; Applicant/Proprietor Exelexis, Inc. D. Penson: Grants, personal fees: Astellas, Medivation, during the conduct of the study; Grants, personal fees: Dendreon, outside the submitted work. G. Attard: Personal fees, non-financial support: Astellas, Medivation, Pfizer, during the conduct of the study; Personal fees: Janssen-Cilag, Veridex, Takeda Sanofi-Aventis Janssen, Roche, Ventana Millenium Pharmaceuticals, Abbott Laboratories, Essa Pharmaceuticals, Bayer Healthcare Pharmaceuticals; Non-financial support: Roche/Ventana, Abbott Laboratories, Essa Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Janssen; Grants: Janssen; AstraZeneca, Arno Therapeutics, Innocrin Pharma; Other: The Institute of Cancer Research (ICR), outside the submitted work. C.N. Sternberg: Oher: Bristol-Myers Squibb, Novartis, Janssen, Bayer, Eisai, MSD, Lilly, Clovis Oncology, Ferring, Pfizer, Astellas Pharma, Sanofi, Ipsen, AstraZeneca, outside the submitted work. D. Phung: Other from Astellas, outside the submitted work. R. Morlock: Personal fees: Astellas, during the conduct of the study; Personal fees: Abbot Medical Optics, Ironwood, Genentech, outside the submitted work. K. Modelska: Other: Pfizer, outside the submitted work. K. Ramaswamy: Other: PfizerInc, during the conduct of the study; Other: Johnson & Johnson, outside the submitted work. C. Ivanescu: Employee: QuintilesIMS, funding statistical analyses (for this work under consultancy contract): Astellas. F. Saad: Grants, personal fees: Astellas, Janssen, during the conduct of the study; Grants, personal fees: Sanofi, Bayer, outside the submitted work.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.